Cradle is a Dutch-Swiss AI software company that accelerates protein engineering for biopharma and industrial biotech. Its cloud-based platform allows scientists to input protein sequences and experimental data, then uses generative AI and machine learning models to suggest improved protein variants — optimising properties such as binding affinity, activity, stability, and expression simultaneously. Teams using Cradle report 2–12× faster development timelines compared with conventional rational design or trial-and-error approaches.

The platform supports all major protein modalities, including antibodies, enzymes, peptides, and vaccines, and is used by customers spanning therapeutics, food ingredients, agricultural solutions, and industrial biotechnology. Notable partnerships include Novo Nordisk (next-generation GLP-1 drug candidates), Johnson & Johnson, Novonesis, Lundbeck (CNS antibody programs), and Hansa Biopharma. As of late 2025, Cradle's platform was powering drug discovery programs for six of the top 25 global pharma companies, with 50+ active projects.

A key differentiator is Cradle's own in-house wet lab in Amsterdam, which continuously generates high-throughput experimental datasets to train and validate the company's foundational models — ensuring reliable model performance even before customer data is ingested. The company is headquartered in Amsterdam (where the lab is based), with offices in Zurich and Boston, and had approximately 100+ employees as of 2026 after doubling headcount in 2025.